Q-omics provides the consensus-scored PYGO1 profile across patient tissues and cancer cell-line models. PYGO1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, PYGO1 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, PYGO1 RNA expression shows 19,676 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight STAD, KIRC, and PDAC as cancer lineages where PYGO1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PYGO1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PYGO1 survival associations across molecular data types. PYGO1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PYGO1 RNA expression–survival associations across cancer types. High PYGO1 expression shows unfavorable associations in STAD, KIRP, UVM and BLCA, but favorable associations in BRCA and UCS. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify STAD as the clearest survival context for PYGO1 RNA expression.
This table summarizes PYGO1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for PYGO1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PYGO1 shows lower tumor expression in KIRC, THCA, KICH, COAD, BRCA and LUAD. The KIRC box plot shows higher PYGO1 RNA expression in normal versus tumor tissue (log2 FC = −1.242, t-test p < 0.001).
This table shows molecular features associated with PYGO1 in patient tissues and cancer cell lines. In patient samples, PYGO1 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, PYGO1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BREAST.
